Market size, growth to 2033 and clinical trials, side by side.
The US is the bigger Over The Counter (OTC) Gastrointestinal Drugs market: $2.4 Bn against $448 Mn in 2023, about 5.3 times as large.
Canada grows faster: 3.9% a year, against 1.9%. The gap still grows from $1.9 Bn to $2.2 Bn by 2033.
Clinical research: 88 active trials in the US, 14 in Canada.
| Measure | ||
|---|---|---|
| Market size, 2023 | $2.4 Bn | $448 Mn |
| Market size, 2033 projected | $2.8 Bn | $657 Mn |
| Growth a year (CAGR) | 1.9% | 3.9% |
| Money added, 2023–2033 | $487 Mn | $209 Mn |
| Share of the world market | 42% | 8% |
| Size rank of 24 countries | #1 | #3 |
| Market per person, 2023 | $6.88 | $11 |
| Active clinical trials | 88 | 14 |
| Full report | US report | Canada report |
US Canada · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
The US is the bigger Over The Counter (OTC) Gastrointestinal Drugs market: $2.4 Bn against $448 Mn in 2023, about 5.3 times as large.
Canada grows faster: 3.9% a year, against 1.9%. The gap still grows from $1.9 Bn to $2.2 Bn by 2033.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.